Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX‐770 (ivacaftor)
Elizabeth Matthes, Julie Goepp, Graeme W. Carlile, et al.
British Journal of Pharmacology (2015) Vol. 173, Iss. 3, pp. 459-470
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Miquéias Lopes‐Pacheco
Frontiers in Pharmacology (2020) Vol. 10
Open Access | Times Cited: 445
CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis
Miquéias Lopes‐Pacheco
Frontiers in Pharmacology (2016) Vol. 7
Open Access | Times Cited: 150
Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells
H. Valley, K. Bukis, Alisa Bell, et al.
Journal of Cystic Fibrosis (2018) Vol. 18, Iss. 4, pp. 476-483
Open Access | Times Cited: 118
Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences
Xiaojiao Xue, Venkateshwar Mutyam, Amita Thakerar, et al.
Human Molecular Genetics (2017) Vol. 26, Iss. 16, pp. 3116-3129
Open Access | Times Cited: 84
Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa
Roxanna Barnaby, Katja Koeppen, Amanda Nymon, et al.
AJP Lung Cellular and Molecular Physiology (2017) Vol. 314, Iss. 3, pp. L432-L438
Open Access | Times Cited: 66
Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis
Emma D. Deeks
Drugs (2016) Vol. 76, Iss. 12, pp. 1191-1201
Closed Access | Times Cited: 63
Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis
Cristina Cigana, Ruggero Giannella, Alice Colavolpe, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 18
Molecular basis of cystic fibrosis: from bench to bedside
Maria Cristina Dechecchi, Anna Tamanini, Giulio Cabrini
Annals of Translational Medicine (2018) Vol. 6, Iss. 17, pp. 334-334
Open Access | Times Cited: 50
Development of HPLC and LC–MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO
Elena K. Schneider‐Futschik, Felisa Reyes‐Ortega, John Wilson, et al.
Journal of Chromatography B (2016) Vol. 1038, pp. 57-62
Open Access | Times Cited: 49
CFTR Correctors and Antioxidants Partially Normalize Lipid Imbalance but not Abnormal Basal Inflammatory Cytokine Profile in CF Bronchial Epithelial Cells
Mieke Veltman, Juan Bautista De Sanctis, Marta Stolarczyk, et al.
Frontiers in Physiology (2021) Vol. 12
Open Access | Times Cited: 39
Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19
Eunjin Hong, Lisa M. Almond, Peter S. Chung, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 111, Iss. 6, pp. 1324-1333
Open Access | Times Cited: 26
Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation
Xin Meng, Yi‐Ting Wang, Xiaomeng Wang, et al.
Journal of Biological Chemistry (2017) Vol. 292, Iss. 9, pp. 3706-3719
Open Access | Times Cited: 48
Mutation-specific downregulation of CFTR2 variants by gating potentiators
Radu G. Avramescu, Yukari Kai, Haijin Xu, et al.
Human Molecular Genetics (2017) Vol. 26, Iss. 24, pp. 4873-4885
Open Access | Times Cited: 44
Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
Elena K. Schneider‐Futschik, Felisa Reyes‐Ortega, Jian Li, et al.
Clinical Pharmacology & Therapeutics (2016) Vol. 101, Iss. 1, pp. 130-141
Open Access | Times Cited: 43
Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation
Deborah M. Cholon, Charles R. Esther, Martina Gentzsch
Expert Review of Precision Medicine and Drug Development (2016) Vol. 1, Iss. 3, pp. 235-243
Open Access | Times Cited: 40
Mutation-specific dual potentiators maximize rescue of CFTR gating mutants
Guido Veit, Dillon F. Da Fonte, Radu G. Avramescu, et al.
Journal of Cystic Fibrosis (2019) Vol. 19, Iss. 2, pp. 236-244
Open Access | Times Cited: 40
Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor
Elena K. Schneider‐Futschik
Drug Metabolism Letters (2018) Vol. 12, Iss. 1, pp. 71-74
Open Access | Times Cited: 39
Physiological and pharmacological characterization of the N1303K mutant CFTR
Samantha DeStefano, Maarten Gees, Tzyh‐Chang Hwang
Journal of Cystic Fibrosis (2018) Vol. 17, Iss. 5, pp. 573-581
Open Access | Times Cited: 38
Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del
Stephanie Chin, Maurita Hung, Amy Won, et al.
Molecular Pharmacology (2018) Vol. 94, Iss. 2, pp. 917-925
Open Access | Times Cited: 37
A novel triple combination of pharmacological chaperones improves F508del-CFTR correction
Graeme W. Carlile, Qi Yang, Elizabeth Matthes, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 35
VX-770-mediated potentiation of numerous human CFTR disease mutants is influenced by phosphorylation level
Guiying Cui, Brandon Stauffer, Barry R. Imhoff, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 35
Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate
Wen‐Ying Lin, Yoshiro Sohma, Tzyh‐Chang Hwang
Molecular Pharmacology (2016) Vol. 90, Iss. 3, pp. 275-285
Open Access | Times Cited: 32
The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis
Lorenzo Guerra, Maria Favia, Sante Di Gioia, et al.
Expert Opinion on Drug Discovery (2020) Vol. 15, Iss. 8, pp. 873-891
Closed Access | Times Cited: 29
Altered iron metabolism in cystic fibrosis macrophages: the impact of CFTR modulators and implications for Pseudomonas aeruginosa survival
Haley F. Hazlett, Thomas H. Hampton, Daniel Aridgides, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 29
Comparative effects of CFTR modulators on phagocytic, metabolic and inflammatory profiles of CF and nonCF macrophages
Daniel Aridgides, Diane Mellinger, L. Gwilt, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top